Alder BioPharmaceuticals, Inc. (ALDR) Forecasted to Earn Q1 2018 Earnings of ($1.00) Per Share
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) – Analysts at Leerink Swann issued their Q1 2018 earnings estimates for shares of Alder BioPharmaceuticals in a report released on Tuesday. Leerink Swann analyst P. Matteis forecasts that the biopharmaceutical company will post earnings per share of ($1.00) for the quarter. Leerink Swann also issued estimates for Alder BioPharmaceuticals’ Q2 2018 earnings at ($1.03) EPS, Q3 2018 earnings at ($0.84) EPS, Q4 2018 earnings at ($0.77) EPS and FY2019 earnings at ($3.34) EPS.
Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.21) by $0.29. During the same period in the previous year, the firm earned ($0.70) earnings per share.
TRADEMARK VIOLATION NOTICE: “Alder BioPharmaceuticals, Inc. (ALDR) Forecasted to Earn Q1 2018 Earnings of ($1.00) Per Share” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/11/09/alder-biopharmaceuticals-inc-aldr-forecasted-to-earn-q1-2018-earnings-of-1-00-per-share.html.
A number of other equities analysts have also recently commented on the company. Mizuho reaffirmed a “buy” rating and issued a $32.00 price target on shares of Alder BioPharmaceuticals in a research note on Wednesday. Canaccord Genuity began coverage on Alder BioPharmaceuticals in a research note on Thursday, October 26th. They issued a “buy” rating and a $20.00 price target on the stock. ValuEngine cut Alder BioPharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 18th. Cowen and Company began coverage on Alder BioPharmaceuticals in a research note on Tuesday, September 26th. They issued an “outperform” rating and a $20.00 price target on the stock. Finally, Royal Bank Of Canada began coverage on Alder BioPharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $17.00 price target on the stock. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $28.07.
Shares of Alder BioPharmaceuticals (ALDR) traded down $0.08 during trading on Thursday, reaching $11.07. The company’s stock had a trading volume of 123,188 shares, compared to its average volume of 965,286. Alder BioPharmaceuticals has a 1-year low of $8.60 and a 1-year high of $34.30.
In other news, insider Mark James Litton sold 16,520 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $12.33, for a total transaction of $203,691.60. Following the transaction, the insider now directly owns 116,452 shares of the company’s stock, valued at $1,435,853.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 10.60% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of ALDR. Teachers Advisors LLC increased its stake in shares of Alder BioPharmaceuticals by 6.3% during the first quarter. Teachers Advisors LLC now owns 81,614 shares of the biopharmaceutical company’s stock valued at $1,698,000 after buying an additional 4,805 shares during the period. Vanguard Group Inc. increased its stake in shares of Alder BioPharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 3,438,702 shares of the biopharmaceutical company’s stock valued at $71,524,000 after buying an additional 194,185 shares during the period. Geode Capital Management LLC increased its stake in shares of Alder BioPharmaceuticals by 21.4% during the first quarter. Geode Capital Management LLC now owns 401,570 shares of the biopharmaceutical company’s stock valued at $8,352,000 after buying an additional 70,691 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Alder BioPharmaceuticals in the first quarter worth $564,000. Finally, Schwab Charles Investment Management Inc. grew its stake in Alder BioPharmaceuticals by 22.3% in the first quarter. Schwab Charles Investment Management Inc. now owns 209,273 shares of the biopharmaceutical company’s stock worth $4,353,000 after purchasing an additional 38,123 shares during the period. 78.57% of the stock is currently owned by hedge funds and other institutional investors.
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.